Using comparative effectiveness research to inform policy and practice in the UK NHS: Past, present and future

PharmacoEconomics

Volumn 28, Issue 10, 2010, Pages 799-811

  Chalkidou, Kalipso ^a   Walley, Tom ^b,c  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b National Institute for Health Research ^*  (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

cost effectiveness; decision making; formularies; research and development; treatment outcome

Indexed keywords

ADALIMUMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CHOLINESTERASE INHIBITOR; EPLERENONE; ETANERCEPT; INFLIXIMAB; MEMANTINE; RANIBIZUMAB; SPIRONOLACTONE; TRANEXAMIC ACID;

COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSIS RELATED GROUP; HEALTH CARE PLANNING; HEALTH CARE POLICY; MEDICAL RESEARCH; NATIONAL HEALTH SERVICE; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

COMPARATIVE EFFECTIVENESS RESEARCH; EVIDENCE-BASED PRACTICE; GREAT BRITAIN; HUMANS; NATIONAL HEALTH PROGRAMS; POLICY;

EID: 77956513759     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535260-000000000-00000     Document Type: Review

References (68)

1. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003 Sep 24; 290 (12): 1624-1632
2. Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009 Jun; 87 (2): 339-367
3. American Recovery and Reinvestment Act of 2009, HR1, 111th Cong.
4. Patient Protection and Affordable Care Act of 2010, HR 3590, 111th Cong.
5. Ellicott C. 'I owe my life to the NHS': Stephen Hawking tells US to stop attacking health service. MailOnline 2009 Aug 13 [online]. Available from URL: http://www.dailymail. co.uk/news/article-1205953/NHS-branded-evil-Orwellian- high-level-US-politicians.html [Accessed 2010 Jun 17]
6. Ferner RE, McDowell SE. A model for NICE in the US. BMJ 2009 Jun; 338: b2221
7. Dhruva SS, Phurrough SE, Salive ME, et al. CMS's landmark decision on CT colonography: examining the relevant data. N Engl J Med 2009 Jun 25; 360 (26): 2699-2701
8. Culyer AJ. Supporting research and development in the National Health Service: a report to the Minister for Health by a research and development task force chaired by Professor Anthony Culyer. London: HMSO, 1994
9. Black N. A national strategy for research and development: lessons from England. Annu Rev Public Health 1997; 18: 485-505
10. Evans I, Thornton H, Chalmers I. Testing treatments: better research for better healthcare. London: The British Library, 2007
11. The House of Lords Select Committee on Science and Technology, Session 1987-1988, 3rd Report. Priorities in Medical Research [HL 54-I, 54-II & 54-III]
12. Department of Health. Research for health. London: HMSO, 1991
13. McCollum C. UK National Health Service R&D funding: a bureaucratic nightmare [letter]. Lancet 2003 May 31; 361 (9372): 1906
14. McNally N, Kerrison S, Pollock AM. Reforming clinical research and development in England. BMJ 2003 Sep 6; 327 (7414): 550-553
15. Culyer AJ. Economics and public policy: NHS research and development as a public good. York: The University of York, 1998
16. Department of Health. Best research for best health: a new national health research strategy [online]. Available from URL: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-4127127 [Accessed 2010 Jun 17]
17. Department of Health, Research and Development [online]. Available from URL: http://www.dh.gov.uk/en/Research anddevelopment/index.htm [Accessed 2010 Jun 17]
18. Horton R. Health research in the UK: the price of success. Lancet 2006 Jul 8; 368 (9530): 93-97
19. National Institute for Health Research. NIHR health technology assessment programme [online]. Available from URL: http://www.hta.ac.uk [Accessed 2010 Jun 17]
20. Walley T. Health technology assessment in England: assessment and appraisal. Med J Aust 2007 Sep 3; 187 (5): 283-285
21. Cooksey D. A review of UK health research funding. London: HM Treasury, 2006
22. Klein P. Live or let die. American Spectator 2009 Aug 14 [online]. Available from URL: http://spectator.org/archives/2009/08/14/live-or-let-die [Accessed 2010 Jun 17]
23. Murdock D. Government medicine kills. National Rev Online 2009 Aug 7 [online]. Available from URL: http://article.nationalreview.com/402410/ government-medicine-kills/deroy-murdock [Accessed 2010 Jun 17]
24. Of NICE and men. Wall Street J 2009 Jul [online]. Available from URL: http://online.wsj.com/article/SB124692973435 303415.html [Accessed 2010 Jun 17]
25. Chalmers I. Minimizing harm and maximizing benefit during innovation in health care: controlled or uncontrolled experimentation? Birth 1986 Sep; 13 (3): 155-164
26. Chalmers I. Well informed uncertainties about the effects of treatments. BMJ 2004 Feb 28; 328 (7438): 475-476
27. Department of Health. Usage of cancer drugs approved by NICE [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicy AndGuidance/DH-4139061 [Accessed 2010 Jun 17]
28. Department of Health. The new NHS. London: Department of Health, 1997
29. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005 Nov 23; 294 (20): 2618-2622
30. Rawlins MD. 5 NICE years. Lancet 2005 Mar 5-11; 365 (9462): 904-908
31. NICE. Identifying subgroups and exploring heterogeneity: guide to the methods for technology appraisals [special workshop; online]. Available from URL: http://www.nice. org.uk/aboutnice/howwework/devnicetech/technology appraisalprocessguides/selectedfurtherreadingguidetothe methodsoftechnologyappraisal.jsp [Accessed 2010 Jun 17]
32. Department of Health. Faster access to modern treatment: how NICE appraisal will work. London: Department of Health, 1999: paragraphs 33-36
33. Chalkidou K, Hoy A, Littlejohns P. Making a decision towait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. J R Soc Med 2007 Oct; 100 (10): 453-460
34. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) 2006 Sep-Oct; 25 (5): 1218-1230
35. Chalmers I. Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility? J R Soc Med 2007 Oct; 100 (10): 440-441
36. Kamerow D. Paying for promising but unproven technologies. BMJ 2007 Nov 10; 335 (7627): 965
37. Pearson SD, Miller FG, Emanuel EJ. Medicare's requirement for research participation as a condition of coverage: is it ethical? JAMA 2006 Aug 23; 296 (8): 988-991
38. Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003 Feb 15; 326 (7385): 388-392
39. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010; 340: c1672
40. National Institute for Health and Clinical Excellence. Key uncertainties in the management and prevention of disease [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/researchanddevelopment/keyuncer tainties.jsp [Accessed 2010 Jun 17]
41. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357: 1598-1607
42. Gray A, Goodacre S, Newby DE, et al., 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 2008; 359: 142-151
43. UK EVAR Trial Investigators, Greenhalgh RM, Brown LC, et al. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med 2010 May 20; 362 (20): 1863-1871
44. Dumville JC, Worthy G, Bland JM, et al., VenUS II team. Larval therapy for leg ulcers (VenUS II): randomised controlled trial. BMJ 2009; 338: b773
45. Peek GJ, Mugford M, Tiruvoipati R, et al., for the CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374: 1351-1363
46. Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371: 57-63
47. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. Epub 2010 Jun 14
48. MRC and NICE to collaborate for the first time on methodology research programme [press release]. 2009 May [online]. Available from URL: http://www.mrc.ac.uk/News publications/News/MRC006081 [Accessed 2010 Jun 17]
49. Department of Health. The 2009 Pharmaceutical Price Regulation Scheme. London: Department of Health, 2009
50. Garber AM, McClellan MB. Satisfaction guaranteed: 'payment by results' for biologic agents. N Engl J Med 2007 Oct 18; 357 (16): 1575-1577
51. Chalkidou K, Lord J, Fischer A, et al. Evidence-based decision making: when should we wait for more information? Health Aff (Millwood) 2008 Nov-Dec; 27 (6): 1642-1653
52. CTEU Bristol. The IVAN trial: a randomised controlled trial ofalternative treatmentstoinhibit VEGFinAge-related choroidal Neovascularisation [online]. Available from URL: http://cteu.bris.ac.uk/trials/ivan/[Accessed 2010 Jun 17]
53. National Eye Institute (NEI). Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial [ClinicalTrials.gov identifier NCT00593450]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 17]
54. National Institute for Health and Clinical Excellence. Department of Health asks NICE to look into Avastin use for eye conditions [press release]. 2010 Mar 30 [online]. Available from URL: http://www.nice.org.uk/newsroom/news/ DHasksNICEtolookintoAvastinuseforeyeconditions. jsp [Accessed 2010 Jun 17]
55. Lillis M. Baucus scoresabig win for big pharma. Washington Independent 2009 Sep [online]. Available from URL: http://washingtonindependent.com/60782/ baucus-scores-a-win-for-big-pharma [Accessed 2010 Jun 17]
56. Appleby J, Philips M. The NHS: satisfied now? In: Park A, Curtice J, Thomson K, et al., editors. British social attitudes, 25th report. London: Sage Publications Ltd, 2009: 25-51
57. Samuelson P. The pure theory of public expenditure. Rev Econ Stat 1954; 36 (4): 387-389
58. Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Aff (Millwood) 2004 Jan-Feb; 23 (1): 107-112
59. Longo WE, Cheadle W, Fink A, et al. The role of the Veterans Affairs Medical Centers in patient care, surgical education, research and faculty development. Am J Surg 2005 Nov; 190 (5): 662-675
60. Cressey D. Health economics: life in the balance. Nature 2009; 461: 336-337
61. Laurance J. NHS watchdog is winning the price war withdrug companies. Independent 2009 Dec 21 [online]. Available from URL: http://www.independent.co. uk/life-style/health-and-families/health-news/nhs-watchdog-is-winning-the-price- war-with-drug-companies-1846352.html [Accessed 2010 Jun 17]
62. Bowcott O, Campbell D. Nice backs minimum pricing on alcohol to cut harmful drinking. Guardian 2009 Oct 13 [online]. Available from URL: http://www.guardian.co.uk/society/2009/oct/13/nice-minimum-pricing-alcohol- health [Accessed 2010 Jun 17]
63. Campbell D, Gupta G. Is public healthcare in the UK as sick as rightwing America claims? Guardian 2009 Aug 11 [online]. Available from URL: http://www.guardian.co.uk/society/2009/aug/11/nhs-sick-healthcare-reform [Accessed 2010 Jun 17]
64. Henderson M. We need cancer drug rationing. Times 2008 Aug 16 [online]. Available from URL: http://www.time sonlineco.uk/tol/life-and-style/health/ article4539008.ece [Accessed 2010 Jun 17]
65. Wishart A. The price of life [television programme]. London: BBC, 2009
66. National Institute for Health and Clinical Excellence. Kennedy study of valuing innovation. London: NICE, 2009 Jul [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/researchanddevelopment/Kennedy StudyOfValuingInnovation.jsp [Accessed 2010 Jun 17]
67. Dillon A. NICE and the definition of innovation. In Vivo Blog 2009 Sep [online]. Available from URL: http://in vivoblog.blogspot.com/2009/09/nice-and- definition-of-inn ovation.html [Accessed 2010 Jun 17]
68. Porter ME, Teisberg EO. Redefining competition in health care. Harv Bus Rev 2004 Jun; 82 (6): 64-76, 136